CORDIS
EU research results

CORDIS

English EN
PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease

Objective

Mitochondrial dysfunction is implicated in Parkinson’s Disease (PD), but detailed understanding of the cause and effect in αSyn toxicity is lacking. Through provision of quantitative and systematic characterisation of mitochondrial dysfunction, PD-MitoQUANT will provide unprecedented understanding of the role of mitochondrial dysfunction in PD, identify and validate novel disease biomarkers, and propose innovative therapeutic targets that can be further progressed by the EFPIA partners. The consortium leverages multi-disciplinary expertise in the fields of αSyn biochemistry, iPSC-derived PD models, mitochondrial function and structural analysis, proteotoxicity, ER stress and UPR signaling, systems biology of mitochondrial function, and in vivo animal models. A key focus will be quantitative description and integrated analysis of mitochondrial function and its relation to proteotoxicity; representing a key panel of consortium partners Prehn [RCSI], Abramov [UCL], Corti [ICM] and Koopmann [RUMC] who also have assembled long–standing expertise in primary neuron culture, iPSC-derived neurons, PD in vivo models, proteostasis and ageing studies. These investigations will be supported by expert teams in iPSC-derived in vitro PD models and in vivo PD models from the academic partners (Hunot [ICM], Melki [CNRS], Di Monte [DZNE], Broccoli [CNR], SME [Mimetas] and EFPIA partners [Teva], [Lundbeck] and [UCB]. Through integrated in vitro, in silico and in vivo approaches, and supported computationally by SME [GENEXPLAIN], PD-MitoQUANT will perform thorough and unprecedented investigations of mitochondrial dysfunction. Finally, the consortium will initiate a European research platform of excellence investigating mitochondrial dysfunction in PD continuing beyond the project, further supported by [PUK]’s PD human tissue biobank. This will provide long-term and sustainable progress in the understanding of mitochondrial dysfunction in PD and towards clinical application.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND

Address

Saint Stephen'S Green 123
2 Dublin

Ireland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 095 123,75

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE

France

EU Contribution

€ 855 375

DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV

Germany

EU Contribution

€ 541 118,75

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 544 635

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 360 587,50

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 403 885

GENEXPLAIN GMBH

Germany

EU Contribution

€ 148 875

MIMETAS BV

Netherlands

EU Contribution

€ 250 835

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 160 000

PINTAIL LTD

Ireland

EU Contribution

€ 137 500

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

Israel

H. LUNDBECK AS

Denmark

UCB BIOPHARMA SPRL

Belgium

PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG

United Kingdom

Project information

Grant agreement ID: 821522

Status

Ongoing project

  • Start date

    1 February 2019

  • End date

    31 January 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 6 959 535

  • EU contribution

    € 4 497 935

Coordinated by:

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland